Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Change in Accured Expenses (2016 - 2025)

Iovance Biotherapeutics has reported Change in Accured Expenses over the past 12 years, most recently at $21.2 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $21.2 million for Q4 2025, up 418.34% from a year ago — trailing twelve months through Dec 2025 was $28.6 million (up 233.84% YoY), and the annual figure for FY2025 was $28.6 million, up 233.84%.
  • Change in Accured Expenses for Q4 2025 was $21.2 million at Iovance Biotherapeutics, up from $5.5 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for IOVA hit a ceiling of $21.2 million in Q4 2025 and a floor of -$23.0 million in Q1 2024.
  • Median Change in Accured Expenses over the past 3 years was $4.8 million (2024), compared with a mean of $4.7 million.
  • Biggest five-year swings in Change in Accured Expenses: crashed 154.2% in 2024 and later surged 418.34% in 2025.
  • Iovance Biotherapeutics' Change in Accured Expenses stood at $9.4 million in 2023, then plummeted by 56.58% to $4.1 million in 2024, then surged by 418.34% to $21.2 million in 2025.
  • The last three reported values for Change in Accured Expenses were $21.2 million (Q4 2025), $5.5 million (Q3 2025), and -$281000.0 (Q2 2025) per Business Quant data.